/CELC
CELC Stock - Celcuity Inc.
Healthcare|BiotechnologyNASDAQ
$101.16+2.02%
+$2.00 (+2.02%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).46
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-1.8%upside
Target: $99.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CELC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$100.15 – $102.17
TARGET (TP)$99.33
STOP LOSS$93.07
RISK/REWARD1:-0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.22
52W High$112.64
52W Low$7.58
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-113,266,951 | $-66,230,331 | $-39,391,091 | $-28,355,915 | $-9,556,164 |
| Net Income | $-111,779,105 | $-63,779,116 | $-40,370,040 | $-29,605,266 | $-9,474,175 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.83 | $-2.69 | $-2.68 | $-2.28 | $-0.89 |
Company Overview
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
86%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$67
Average Target
↓ 33.3% Downside
Now
$27
Low
$67
Average
$126
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Wells Fargo | Initiation | Overweight | $126 |
| November 18th 2025 | Wolfe Research | Initiation | Outperform | $110 |
| November 17th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| September 22nd 2025 | Guggenheim | Initiation | Buy | $110 |
| July 1st 2025 | Stifel | Resumed | Buy | $30 |
| July 22nd 2024 | Leerink Partners | Initiation | Outperform | $29 |
| February 22nd 2024 | Stifel | Initiation | Buy | $40 |
| December 8th 2023 | H.C. Wainwright | Initiation | Buy | $27 |
Earnings History & Surprises
CELCBeat Rate
37%
Last 19 quarters
Avg Surprise
-19.0%
EPS vs Estimate
Beats / Misses
7/12
Last 12 quarters
Latest EPS
$-0.92
Q4 2025
EPS Surprise History
Q1 24
+8.5%
$-0.65vs$-0.71
Q2 24
+9.9%
$-0.64vs$-0.71
Q3 24
+12.7%
$-0.62vs$-0.71
Q4 24
-7.7%
$-0.70vs$-0.65
Q1 25
-18.1%
$-0.85vs$-0.72
Q2 25
+9.5%
$-0.86vs$-0.95
Q3 25
-15.6%
$-1.04vs$-0.90
Q4 25
+9.8%
$-0.92vs$-1.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-1.06 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.02 | $-0.92 | +9.8% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.90 | $-1.04 | -15.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.95 | $-0.86 | +9.5% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.72 | $-0.85 | -18.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.65 | $-0.70 | -7.7% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.71 | $-0.62 | +12.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.71 | $-0.64 | +9.9% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.71 | $-0.65 | +8.5% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.74 | $-0.83 | -12.2% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.67 | $-0.66 | +1.5% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.65 | $-0.55 | +15.4% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.54 | $-0.69 | -27.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.49 | $-0.75 | -53.1% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.47 | $-0.67 | -42.6% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.51 | $-0.53 | -3.9% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-0.40 | $-0.45 | -12.5% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.38 | $-1.11 | -192.1% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.20 | $-0.25 | -25.0% | ✗ MISS |
Latest News
Celcuity shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a $126 price target.
📈 PositiveBenzinga•Dec 12, 2025, 06:45 PM
Wells Fargo Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $126
📈 PositiveBenzinga•Dec 12, 2025, 04:35 PM
Celcuity Announces Updated Results From Randomized, Phase 3 VIKTORIA-1 Trial For Gedatolisib, At 2025 SABCS
📈 PositiveBenzinga•Dec 11, 2025, 07:38 PM
Celcuity To Present Updated Data From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial At The 2025 San Antonio Breast Cancer Symposium December 9-12, 2025
➖ NeutralBenzinga•Nov 26, 2025, 09:08 PM
Celcuity shares are trading higher after the company announced it submitted its New Drug Application to the FDA for gedatolisib in hormone receptor positive, human epidermal growth factor receptor 2 negative, advanced breast cancer
📈 PositiveBenzinga•Nov 20, 2025, 01:53 PM
Wolfe Research Initiates Coverage On Celcuity with Outperform Rating, Announces Price Target of $110
📈 PositiveBenzinga•Nov 18, 2025, 04:42 PM
Celcuity Completes Submission Of New Drug Application To FDA For Gedatolisib In HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
📈 PositiveBenzinga•Nov 17, 2025, 09:07 PM
HC Wainwright & Co. Downgrades Celcuity to Neutral, Raises Price Target to $94
➖ NeutralBenzinga•Nov 17, 2025, 12:13 PM
Craig-Hallum Maintains Buy on Celcuity, Raises Price Target to $108
📈 PositiveBenzinga•Nov 13, 2025, 05:48 PM
Celcuity shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.
📈 PositiveBenzinga•Nov 12, 2025, 09:03 PM
Celcuity Q3 Adj. EPS $(0.78) Beats $(1.01) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:02 PM
HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $77
📈 PositiveBenzinga•Oct 22, 2025, 11:49 AM
Celcuity soars on phase 3 data for gedatolisib in breast cancer
📈 PositiveSeeking Alpha•Oct 20, 2025, 02:50 PM
Celcuity shares are trading higher after the company presented Phase 1 data at ESMO 2025 showing its gedatolisib plus darolutamide combination delivered a 9.1-month median rPFS in mCRPC with a favorable safety profile and no treatment-related discontinuations.
📈 PositiveBenzinga•Oct 20, 2025, 11:39 AM
Needham Reiterates Buy on Celcuity, Maintains $70 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 10:10 AM
Reported Saturday, Celcuity Presented Phase 1 Data At ESMO 2025 Showing Gedatolisib Plus Darolutamide Delivers 9.1-Month Median rPFS In mCRPC With Favorable Safety Profile And No TRAE-Related Discontinuations
📈 PositiveBenzinga•Oct 20, 2025, 08:18 AM
Reported Saturday, Celcuity Announces Phase 3 VIKTORIA-1 Data: Gedatolisib Triplet Reduces Risk of Progression or Death by 76% in HR+/HER2- PIK3CA Wild-Type Advanced Breast Cancer
📈 PositiveBenzinga•Oct 20, 2025, 08:16 AM
Needham Reiterates Buy on Celcuity, Maintains $70 Price Target
📈 PositiveBenzinga•Oct 3, 2025, 10:38 AM
Celcuity To Present Phase 3 VIKTORIA-1 Breast Cancer Data In Late-Breaking Oral Session At ESMO 2025
📈 PositiveBenzinga•Sep 22, 2025, 01:17 PM
Guggenheim Initiates Coverage On Celcuity with Buy Rating, Announces Price Target of $110
📈 PositiveBenzinga•Sep 22, 2025, 10:57 AM
Frequently Asked Questions about CELC
What is CELC's current stock price?
Celcuity Inc. (CELC) is currently trading at $101.16 per share. The stock has moved +2.02% today.
What is the analyst price target for CELC?
The average analyst price target for CELC is $99.33, based on 1 analyst.
What sector is Celcuity Inc. in?
Celcuity Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CELC's market cap?
Celcuity Inc. has a market capitalization of $4.68 billion, making it a mid-cap company.
Does CELC pay dividends?
No, Celcuity Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to CELC for comparison